Tags : Health Canada Approval

BMS’s Reblozyl (luspatercept) Receives Health Canada Approval for Beta Thalassemia

Shots:   The approval is based on the P-lll BELIEVE study assessing Reblozyl (luspatercept) + BSC vs PBO + BSC in adult patients with anemia associated with beta-thalassemia requiring regular RBC transfusions Result: ≥33% reduction in RBC transfusion with a reduction of ≥2units from 13-24wks. (21.4% vs. 4.5%), results were published in NEJM Reblozyl regulate late-stage […]Read More